Imstem Biotechnology, a spinout from Connecticut, has won a patent for its stem cell-based treatment of autoimmune diseases such as multiple sclerosis.
Imstem Biotechnology, a US-based stem cell technology spinout from University of Connecticut, has been awarded a joint patent with the institution for a stem cell-based treatment of autoimmune diseases.
ImStem’s T-MSC cell therapy is primarily aimed at sufferers of multiple sclerosis, a condition affecting the brain and spinal cord that can cause impairment to vision, balance and movement of the arms or legs.
The approach builds on ImStem discovering that embryonic stem cells are more effective against autoimmune diseases than…
